BACKGROUND Increasing availability and use of long-acting injectable antipsychotics have generated a need to compare these formulations with their oral equivalents; however, a paucity of relevant data is available. METHODS This post hoc comparison of the long-term efficacy, safety and tolerability of maintenance treatment with paliperidone palmitate (PP) versus oral paliperidone extended rele...

To the Editor: Paliperidone palmitate is a long-acting injectable (LAI) antipsychotic, approved for treatment of schizophrenia in adults.1 It is the major active metabolite of risperidone and, in its injectable form, has several potential advantages over other LAIs. It reaches steady state within 4 to 8 days, so patients are not required to take oral supplementation at initiation of therapy.2 I...

BACKGROUND Paliperidone palmitate (PP) is a long-acting injectable formulation of an atypical antipsychotic, paliperidone. Its dose can be expressed in milligram or milligram equivalents (mg eq) of active paliperidone (39, 78, 117, 156, and 234 mg of PP correspond to 25, 50, 75, 100, and 150 mg eq of paliperidone). The recommended initiation dosing regimen for PP is 150 [day 1]/100[day 8] mg eq...

OBJECTIVE The Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study compared the effects of once-monthly paliperidone palmitate with daily oral antipsychotics on treatment failure in adults with schizophrenia. METHOD The PRIDE study is a 15-month, randomized, multicenter study (May 5, 2010, to December 9, 2013) of adult subjects with a DSM-IV diagnosis of schizophrenia ...

OBJECTIVE The aim of the present study was to examine the effects of a new antipsychotic drug paliperidone palmitate on hemogram and coagulation parameters in rats. MATERIALS AND METHODS Experiments were performed on 22 female albino Wistar rats (8-12 weeks old). Control group was given drinking water as vehicle (0.3 mL). PAL-1 rats were given 1 mg/kg paliperidone palmitate (in 0.3 mL drinkin...

I this issue of The Journal of Clinical Psychiatry, Fu et al1 report on the results of a study of paliperidone palmitate once-monthly in patients diagnosed with schizoaffective disorder. In this well-designed and well-executed trial, paliperidone monthly was used either as monotherapy or as an adjunct to mood stabilizers or antidepressants. The subjects were randomized to continue paliperidone ...

BACKGROUND Previous meta-analyses have compared paliperidone extended-release (ER) tablets with other antipsychotics, but none have involved Chinese patients or studies from People's Republic of China. Further, the results of these meta-analyses may not be applicable to Chinese patients. In the present study, we evaluated the efficacy, safety, and acceptability of paliperidone ER compared with ...

Objective: Many evidences suggested that impairment of glutathione-dependent system is observed in the brain of schizophrenic patients. GSH is an important substrate of glutathione peroxidase (GPx). It is recognized that selenium-dependent GPx (GPx-1) out of GPx isozymes provides a first line of defense against peroxides. Thus, we investigated in the present study a role of GPx-1 gene in schizo...

Objective: Many evidences suggested that impairment of glutathione-dependent system is observed in the brain of schizophrenic patients. GSH is an important substrate of glutathione peroxidase (GPx). It is recognized that selenium-dependent GPx (GPx-1) out of GPx isozymes provides a first line of defense against peroxides. Thus, we investigated in the present study a role of GPx-1 gene in schizo...

Paliperidone, an active metabolite of risperidone, is a new atypical antipsychotic agent. Syndrome of inappropriate antidiuretic hormone (SIADH), neuroleptic malignant syndrome (NMS), and rhabdomyolysis are the uncommon side effects of psychotropic drugs. We report a case of 35-year-old male with schizoaffective disorder who was admitted for acute-on-chronic exacerbation of his psychotic disord...